MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Go back to MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review| Miracle Applications Corp (NASDAQ: MIRA) | Delayed: 0.76 +0.04 (5.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.72 | 52 Week High | $0.04 | |||
| Open | $0.73 | 52 Week Low | $0.00 | |||
| Day High | $0.76 | P/E | N/A | |||
| Day Low | $0.72 | EPS | $0.00 | |||
| Volume | 136,576 | |||||
